KR830009037A - 헤테로고리 카르복사미드의 제조방법 - Google Patents
헤테로고리 카르복사미드의 제조방법 Download PDFInfo
- Publication number
- KR830009037A KR830009037A KR1019820000910A KR820000910A KR830009037A KR 830009037 A KR830009037 A KR 830009037A KR 1019820000910 A KR1019820000910 A KR 1019820000910A KR 820000910 A KR820000910 A KR 820000910A KR 830009037 A KR830009037 A KR 830009037A
- Authority
- KR
- South Korea
- Prior art keywords
- group
- methyl
- carboxamide
- quinoline
- dihydro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
- C07D455/03—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
- C07D455/04—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyrrole Compounds (AREA)
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (9)
- 카르복실산(III)이나 그것의 반응 유도체와 아민 R5R13NH이나 그것의 반응 유도체를 반응시켜서 다음 일반식(I)의 화합물을 제조하거나, 혹은(이 식에서 A1,A2,R1,R2,R3및 R4는 다음 식(I)에서 정의되는 바와 같다).디카르복실산(IV)의 반응 유도체와 아민(V)을 반응시켜서 A1이 OH이고 A2가 0인 다음 일반식(I)의 화합물을 제조하거나, 혹은(이 식에서 R1,R2,R3,R4,R9,R10,R11및 R13은 일반식(I)에서 정의되는 바와 같다).이사토산 무수물(VI)의 유도체와 산(VII)의 저급 알킬 에스테르와 반응시켜 R1이 OH이고 A2가 0인 일반식(I)의 화합물을 제조하거나 니트릴(VIII)과 반응시켜 A1이 OH이고 A2가 NH인 일반식(I)의 화합물을 제조하거나, 혹은(이 식에서 1R1,R2,R3및 R4는 일반식(I)에서 정의되는 바와 같다).R5R13NCOCH2COOH (VII)(이 식에서 R5와 R13은 일반식(I)에서 정의되는 바와 같다).R5R13NCOCH2CN (VIII)(이 식에서 R5와 R13은 일반식(I)에서 정의되는 바와 같다).X가 할로겐인 일반식(IX)의 화합물과 A1H(A1은 일반식(I)에서 정의되는 바와 같다)나 그것의 반응 유도체와 반응시켜서 A2가 0인 일반식(I)의 화합물을 제조하는 방법에 있어서, 앞에서 언급한 반응을 하는 동안에 필요하다면 통상적인 방법에 의하여 감수성기를 보호한 다음 일반식(I)의 화합물을 수득하기 위한 바람직한 기로 전환시키고, 필요하다면 통상적인 방법에 의하여 일반식(I)의 화합물내에 있는 A1,A2,R1,R2,R3,R4,R5및 R13치환체중에서 한개 이상의 치환체를 일반식(I)에서 정의되는 다른 치환체로 전환시킬 수 있으며, 필요하다면 앞에서 기술한 반응에 의하여 수득된 일반식(I)의 화합물들을 약제학적으로 수락되는 염으로 전환시키고, 앞에서 기술한 모든 반응들을 임의적으로 촉매가 존재하는 반응조건에서 반응물이나 반응생성물들과 반응하지 않는 용매존재하에서 진행시킴을 특징으로 하는 일반식(I)의 화합물인 헤테로고리 카르복사미드와 그것의 토오토머를 제조하는 방법.(이 식에서 A1과 A2는 3,4-이중결합보다는 2,3-이중결합으로 서로 교환되고, 서로 같거나 다를 수도 있는 R1,R2및 R3는 수소, 저급 알킬기, 저급 알콕시기, 할로겐기, NO2OH,OCOR8,NR6R7및 NR6COR8등으로 이루어진 기중에서 선택되며, 또한 R1과 R2또는 R2와 R3는 메틸렌디옥시기를 형성할 수 있으며;R4는 저급알킬기, 저급알케닐기, 퀴놀린 고리중 8-위치의 탄소원자와 고리를 형성하는 저급 알킬렌기, 저급 알킬기, 저급 알콕시기, OH 및 OCOR8으로 이루어진 기중에서 선택한 치환체로 단일치환 혹은 이치환된 시클로알킬기 및 저급알킬기, 저급 알콕시기 및 할로겐기(특히 F, Cl 및 Br)로 이루어진 기중에서 선택한 치환체로 단일치환 혹은 이치환된 페닐기이고;R5는 S와 N으로 이루어진 기 중에서 선택한 기껏해야 2개의 헤테로 원자들을 함유하고 있는 오각형이나 육각형으로 된 헤테로고리와 저급 알킬기, 저급 알콕시기 및 할로겐(특히 F와 Cl)으로 이루어진 기 중에서 선택한 치환체들로 단일치환 혹은 이치환된 오각형이나 육각형 헤테로고리 및 다음기(II)로 이루어진 기중에서 선택되고;(이 식에서 서로 같거나 다를 수도 있는 R9,R10및 R11은 수소, 저급 알킬기, 저급 알케닐기, 저급 알콕시기, 저급 알킬티오기, 할로겐기, CN,SO2CH3, OH, OCOR8, NR6R7, NR6COR8, COOR12, OCH2COOR12,CH2COOR12,COR8및 m이 4 또는 5인 -N(CH2)m 이고; 또한 R9와 R10혹은 R10과 R11은 메틸렌디옥시기를 형성할 수 있다).A1은 OR12,OCOR8, NR6R7및 NR6COR8으로 이루어진 기중에서 선택되고 A2는 0와 NR6로 이루어진 기중에서 선택되고;R6과 R7은 수소와 저급 알킬기로 이루어진 기중에서 선택되고;R8은 저급 알킬기이고; R12는 저급 알킬기와 M(수소와 약제학적으로 수락되는 무기성 및 유기성 양이온 중에서 선택된)으로 이루어진 기중에서 선택되고; R13은 OH,OR8및 OCOR8으로 이루어진 기중에서 선택된 치환체로 치환되는 저급 알킬기, 수소 및 저급 알케닐기 등으로 이루어진 기중에서 선택되고; R9,R10및 R11이 저급 알킬기, 저급 알케닐기 및 저급 알콕시기, 약제학적으로 수락되는 무기성 혹은 유기성 산으로 이루어진 부가염등으로 이루어진 기중에서 선택되면 R13은 OH,OR8및 OCOR8등으로 이루어진 기중에서 선택된 치환체로 치환된 저급 알킬기 및 저급 알케닐기로부터 선택된다.
- 제1항에 있어서, R13은 임의적으로 치환된 저급 알킬기나 저급 알케닐기로 이루어진 기중에서 선택되고 A1은 OH이고 A2는 0이고 R4는 저급 알킬기이고 R5는 앞에서 정의된 기(II) 임을 특징으로 한 헤테로고리 카르복사미드의 제조방법.
- 제1항에 있어서, R13은 수소이고 R4는 저급 알킬기이고 R5는 헤테로고리임을 특징으로 하는 헤테로고리 카르복사미드의 제조방법.
- 제1항에 있어서, A1은 NR6R7이나 NR6COR8으로 이루어진 기중에서 선택되고 A2는 0이고 R4는 저급알킬기이고 R5는 앞에서 정의된 기(II)이고 R6, R7및 R8은 일반식(I)에서 정의된 바와 같은 것임을 특징으로한 헤테로고리 카르복사미드의 제조방법.
- 제1항에 있어서 R13은 수소이고 R5는 앞에서 정의된 바와 같은 기(II)이고 R9,R10및 R11은 할로겐, OH,OCOR8,NR6R7,NR6COR8, -N(CH2)m, COOR12,OCH2COOR12및 CH2COOR12(R6,R7,R8,R12및 m은 앞에서 정의된 바와 같다)등으로 이루어진 기중에서 선택됨을 특징으로 한 헤테로고리 카르복사미드의 제조방법.
- 제1항에 있어서, R4가 퀴놀린 고리중 8-위치에 있는 탄소원자와 고리를 형성하는 저급 알킬렌기임을 특징으로 하는 헤테로고리 카르복사미드의 제조방법.
- 제1,3 혹은 6항중 어느 한가지 항에 있어서, R5가 피리딘, 피라졸, 이미다졸, 이소티아졸, 티아졸, 피리다솔, 피리미딘 및 피라진 등으로 이루어진 기중에서 선택된 것임을 특징으로 한 헤테로고리 카르복사미드의 제조방법.
- 제1-7항중 어느 한가지 항에 있어서, R1,R2및 R3치환체중 적어도 2개의 치환체가 수소이고 R5가 앞에서 정의된 기(II)일때 R9, R10및 R11치환체중 적어도 한개의 치환체가 수소임을 특징으로 한 헤테로고리 카르복사미드의 제조방법.
- 제1항에 있어서, 다음 화합물들을 제조하고 또한 필요하다면 통상적인 방법에 의하여 약학적으로 수락되는 무기성 혹은 유기성 양이온과 반응시켜 염으로 전환시키거나 약제학적으로 수락되는 무기산이나 유기산으로 반응시켜 부가염으로 전환시킴을 특징으로 한 헤테로고리 카르복사미드의 제조방법.a) N-(4-디메틸아미노페닐)-1, 2-디히드로-4-히드록시-1-메틸-2-옥소-퀴놀린-3-카르복사미드.b) N-(4-카르복시메틸페닐)-1, 2-디히드로-4-히드록시-1-메틸-2-옥소-퀴놀린-3-카르복사미드.c) N-(4-히드록시페닐)-1, 2-디히드로-4-히드록시-1-메틸-2-옥소-퀴놀린-3-카르복사미드.d) N-페닐-N-메틸-1, 2-디히드로-4-히드록시-1-메틸-2-옥소-퀴놀린-3-카르복사미드.e) N-페닐-1, 2-디히드로-1,8-에틸렌-4-히드록시-2-옥소-퀴놀린-3-카르복사미드.f) N-페닐-1, 2-디히드로-4-히드록시-2-옥소-1,8-트리메틸렌-퀴놀린-3-카르복사미드.g) N-(2-티아졸린)-1, 2-디히드로-4-히드록시-1-메틸-2-옥소-퀴놀린-3-카르복사미드.h) N-메틸-N-페닐-4-아미노-1, 2-디히드로-1-메틸-2-옥소-퀴놀린-3-카르복사미드.i) N-메틸-N-(2-티아졸릴)-4-아미노1, 2-디히드로-1-메틸-2-옥소-퀴놀린-3-카르복사미드.j) N-페닐-1, 2-디히드로-4-히드록시-2-이미노-1-메틸-퀴놀린-3-카르복사미드.k) N-메틸-N-페닐-1, 2-디히드로-4-히드록시-2-옥소-1,8-트리메틸렌-퀴놀린-3-카르복사미드.l) N-메틸-N-페닐-1, 2-디히드로-6-디메틸아미노-4-히드록시-1-메틸-2-옥소-퀴놀린-3-카르복사미드.m) N-(2-이미다졸일)-N-메틸-1, 2-디히드로-4-히드록시-1-메틸-2-옥소-퀴놀린-3-카르복사미드.n) N-(2-메톡시페닐)-N-메틸-1, 2-디히드로-4-히드록시-1-메틸-2-옥소-퀴놀린-3-카르복사미드.o) N-메틸-N-(2-피리딜)-1,2-디히드로-4-히드록시-1-메틸-2-옥소-퀴놀린-3-카르복사미드.p) N-(4-클로로페닐)-N-메틸-1, 2-디히드로-4-히드록시-1-메틸-2-옥소-퀴놀린-3-카르복사미드.q) N-메틸-N-피라지닐-1, 2-디히드로-4-히드록시-1-메틸-2-옥소-퀴놀린-3-카르복사미드.r) N-메틸-N-(2-티아졸일)1, 2-디히드로-4-히드록시-1-메틸-2-옥소-퀴놀린-3-카르복사미드.s) N-메틸-N-피리지닐-1,2-디히드로-4-히드록시-1-메틸-2-옥소-퀴놀린-3-카르복사미드.t) N-메틸-N-(2-티아졸일)-1, 2-디히드로-1,8-에틸렌-4-히드록시-2-옥소-퀴놀린-3-카르복사미드.u) N-(2-히드록시페닐)-N-메틸-1, 2-디히드로-4-히드록시-1-메틸-2-옥소-퀴놀린-3-카르복사미드.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB8106594 | 1981-03-03 | ||
GB8106594 | 1981-03-03 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR830009037A true KR830009037A (ko) | 1983-12-17 |
KR860001876B1 KR860001876B1 (ko) | 1986-10-24 |
Family
ID=10520089
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR8200910A KR860001876B1 (ko) | 1981-03-03 | 1982-03-03 | 헤테로고리 카르복사미드의 제조방법 |
Country Status (21)
Country | Link |
---|---|
US (2) | US4547511A (ko) |
EP (1) | EP0059698B1 (ko) |
JP (1) | JPS57171975A (ko) |
KR (1) | KR860001876B1 (ko) |
AT (1) | ATE15798T1 (ko) |
AU (1) | AU547849B2 (ko) |
CA (1) | CA1182455A (ko) |
DE (1) | DE3266464D1 (ko) |
DK (1) | DK157859C (ko) |
ES (1) | ES8400409A1 (ko) |
FI (1) | FI79532C (ko) |
GR (1) | GR76073B (ko) |
HK (1) | HK38689A (ko) |
HU (1) | HU186909B (ko) |
IE (1) | IE52670B1 (ko) |
IL (1) | IL65028A (ko) |
NO (1) | NO163130C (ko) |
NZ (1) | NZ199888A (ko) |
PH (1) | PH18520A (ko) |
PT (1) | PT74512B (ko) |
ZA (1) | ZA821210B (ko) |
Families Citing this family (96)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3269753A (en) * | 1964-08-31 | 1966-08-30 | Data Man Inc | Bookkeeping unit |
IE52670B1 (en) * | 1981-03-03 | 1988-01-20 | Leo Ab | Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation |
US4400017A (en) * | 1981-03-04 | 1983-08-23 | Pendergrass Russell G | Integrated budget and check record book |
US4650804A (en) * | 1984-03-30 | 1987-03-17 | Fujisawa Pharmaceutical Co., Ltd. | Quinolizinone compounds and pharmaceutical composition comprising the same, useful as anti-ulcerative and anti-allergic agents |
DE3420116A1 (de) * | 1984-05-30 | 1985-12-05 | Bayer Ag, 5090 Leverkusen | Immunstimulierende mittel |
US4786644A (en) * | 1987-11-27 | 1988-11-22 | Hoechst-Roussel Pharmaceuticals Inc. | 1-aryl-3-quinolinecarboxamide |
IT1228293B (it) * | 1989-02-06 | 1991-06-07 | Angeli Inst Spa | Benzoderivati di composti eterociclici contenenti azoto. |
US5310913A (en) * | 1989-06-09 | 1994-05-10 | Kabi Pharmacia Aktiebolag | Derivatives of quinoline-3-carboxanilide |
SE8902076D0 (sv) * | 1989-06-09 | 1989-06-09 | Pharmacia Ab | Derivatives of quinoline-3-carboxanilide |
SE9000624D0 (sv) * | 1990-02-22 | 1990-02-22 | Pharmacia Ab | New use |
US5691350A (en) * | 1990-02-22 | 1997-11-25 | Kabi Pharmacia Ab | Use of linomide for treatment of retrovirus infections specifically HIV infections |
US5504092A (en) * | 1990-03-27 | 1996-04-02 | Pharmacia Ab | Use of Linomide to increase hemopoietic cell precursors |
SE9001111D0 (sv) * | 1990-03-27 | 1990-03-27 | Pharmacia Ab | Supportive use |
CA2091173A1 (en) * | 1990-09-07 | 1992-03-08 | Adriano Afonso | Antiviral compounds and antihypertensive compounds |
AU8665991A (en) * | 1990-09-07 | 1992-03-30 | Schering Corporation | Antiviral compounds and antihypertensive compounds |
WO1992004326A1 (en) * | 1990-09-07 | 1992-03-19 | Schering Corporation | Antiviral compounds |
US5219864A (en) * | 1991-03-12 | 1993-06-15 | Kyowa Hakko Kogyo Co., Ltd. | Thienopyridine derivatives |
GB9108547D0 (en) * | 1991-04-22 | 1991-06-05 | Fujisawa Pharmaceutical Co | Quinoline derivatives |
SE469368B (sv) | 1991-10-09 | 1993-06-28 | Kabi Pharmacia Ab | Ny anvaendning av linomide foer tillverkning av laekemedel foer behandling av multiple sclerosis (ms) |
TW222276B (ko) * | 1992-01-27 | 1994-04-11 | Fujisawa Pharmaceutical Co | |
SE9201076L (sv) * | 1992-04-06 | 1993-10-07 | Shimon Slavin | Användningen av gamla läkemedel för behandling av diabetes |
GB9311562D0 (en) * | 1993-06-04 | 1993-07-21 | Fujisawa Pharmaceutical Co | Heterocyclic derivatives |
SE9302490D0 (sv) * | 1993-07-26 | 1993-07-26 | Kabi Pharmacia Ab | New use of old drugs |
GB9404378D0 (en) * | 1994-03-07 | 1994-04-20 | Fujisawa Pharmaceutical Co | Quinoline derivatives |
SE9400810D0 (sv) * | 1994-03-10 | 1994-03-10 | Pharmacia Ab | New use of Quinoline-3-carboxamide compounds |
SE9400809D0 (sv) * | 1994-03-10 | 1994-03-10 | Pharmacia Ab | New use of quinoline-3-carboxamide compounds |
CA2222471A1 (en) * | 1996-03-27 | 1997-10-02 | Toray Industries, Inc. | Ketone derivatives and medical application thereof |
US5912349A (en) * | 1997-01-31 | 1999-06-15 | Pharmacia & Upjohn Company | Process for the preparation of roquinimex |
JPH1171351A (ja) * | 1997-08-29 | 1999-03-16 | Ss Pharmaceut Co Ltd | 置換キノロン誘導体及びこれを含有する医薬 |
US6077851A (en) * | 1998-04-27 | 2000-06-20 | Active Biotech Ab | Quinoline derivatives |
SE9801474D0 (sv) * | 1998-04-27 | 1998-04-27 | Active Biotech Ab | Quinoline Derivatives |
SE9802549D0 (sv) * | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
US6133285A (en) * | 1998-07-15 | 2000-10-17 | Active Biotech Ab | Quinoline derivatives |
SE9802550D0 (sv) * | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
US6121287A (en) * | 1998-07-15 | 2000-09-19 | Active Biotech Ab | Quinoline derivatives |
JP2000044560A (ja) * | 1998-07-31 | 2000-02-15 | Kyorin Pharmaceut Co Ltd | ベンゾキノリジン誘導体及びその製造方法 |
JP2000044561A (ja) * | 1998-07-31 | 2000-02-15 | Kyorin Pharmaceut Co Ltd | ピロロキノリン誘導体及びその製造方法 |
JP2000256323A (ja) | 1999-01-08 | 2000-09-19 | Japan Tobacco Inc | 2−オキソキノリン化合物及びその医薬用途 |
SE0002320D0 (sv) * | 1999-10-25 | 2000-06-21 | Active Biotech Ab | Malignant tumors |
RS51019B (sr) | 1999-10-25 | 2010-10-31 | Active Biotech Ab. | Lekovi za lečenje malignih tumora |
AU1302301A (en) * | 1999-11-08 | 2001-06-06 | Sankyo Company Limited | Nitrogenous heterocycle derivatives |
US6525049B2 (en) | 2000-07-05 | 2003-02-25 | Pharmacia & Upjohn Company | Pyrroloquinolones as antiviral agents |
JP2003012667A (ja) * | 2001-06-26 | 2003-01-15 | Rrf Kenkyusho:Kk | キノリンカルボキサミド骨格を有する抗菌剤 |
US6822097B1 (en) * | 2002-02-07 | 2004-11-23 | Amgen, Inc. | Compounds and methods of uses |
US6875869B2 (en) * | 2002-06-12 | 2005-04-05 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
SE0201778D0 (sv) * | 2002-06-12 | 2002-06-12 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
US7560557B2 (en) * | 2002-06-12 | 2009-07-14 | Active Biotech Ag | Process for the manufacture of quinoline derivatives |
US7893096B2 (en) | 2003-03-28 | 2011-02-22 | Novartis Vaccines And Diagnostics, Inc. | Use of small molecule compounds for immunopotentiation |
WO2004104000A1 (ja) * | 2003-05-23 | 2004-12-02 | Japan Tobacco Inc. | トリサイクリック縮合環化合物およびその医薬用途 |
SE0400235D0 (sv) * | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
US8314124B2 (en) | 2004-02-06 | 2012-11-20 | Active Biotech Ab | Crystalline salts of quinoline compounds and methods for preparing them |
WO2006115509A2 (en) | 2004-06-24 | 2006-11-02 | Novartis Vaccines And Diagnostics Inc. | Small molecule immunopotentiators and assays for their detection |
EP2277595A3 (en) | 2004-06-24 | 2011-09-28 | Novartis Vaccines and Diagnostics, Inc. | Compounds for immunopotentiation |
US7228698B2 (en) * | 2005-06-30 | 2007-06-12 | Premark Feg L.L.C. | Refrigeration unit |
WO2007038571A2 (en) * | 2005-09-26 | 2007-04-05 | Smithkline Beecham Corporation | Prolyl hydroxylase antagonists |
BRPI0617477A2 (pt) * | 2005-10-19 | 2011-07-26 | Teva Pharma | mistura de partÍculas cristalinas de laquinimod sàdica, composiÇço, processo de cristalizaÇço de laquinimod sàdica, laquinimod sàdica, e, processo para produzir uma composiÇço farmacÊutica |
EP1960363B1 (en) * | 2005-12-09 | 2014-01-22 | Amgen, Inc. | Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions and uses thereof |
WO2007124617A1 (fr) * | 2006-04-28 | 2007-11-08 | Institute Of Mataria Medica, Chinese Academy Of Medical Sciences | Dérivés de coumarine, leurs procédés de préparation, compositions pharmaceutiques et utilisations |
EP2035001B1 (en) | 2006-06-12 | 2011-11-09 | Teva Pharmaceutical Industries Limited | Stable laquinimod preparations |
PL2682120T3 (pl) * | 2007-12-20 | 2017-02-28 | Teva Pharmaceutical Industries, Ltd. | Stabilne preparaty lakwinimodu |
PL2276740T3 (pl) * | 2008-04-28 | 2015-01-30 | Actavis Group Ptc Ehf | Ulepszony sposób wytwarzania pochodnych chinolino-3-karboksyamidowych |
BRPI0913518A2 (pt) * | 2008-09-03 | 2016-07-26 | Teva Pharma | composto, composição farmacêutica, e, método de tratamento de um distúrbio mediado por função imune |
SI2349263T1 (sl) | 2008-10-23 | 2014-09-30 | Vertex Pharmaceuticals Incorporated | Modulatorji cistiäśno-fibroznega transmembranskega regulatorja prevodnosti |
WO2010059549A1 (en) * | 2008-11-18 | 2010-05-27 | Glaxosmithkline Llc | Prolyl hydroxylase inhibitors |
US20120009226A1 (en) * | 2008-12-17 | 2012-01-12 | Actavis Group Ptc Ehf | Highly pure laquinimod or a pharmaceutically acceptable salt thereof |
ME02414B (me) * | 2009-07-30 | 2016-09-20 | Teva Pharma | Tretman kronove bolesti lakvinimodom |
EP3064206B1 (en) * | 2009-08-10 | 2019-03-20 | Active Biotech AB | Treatment of huntington's disease using laquinimod |
BR112012021905A2 (pt) * | 2010-03-03 | 2015-09-29 | Teva Pharma | tratamento de nefrite lúpica usando laquinimod |
PT2542080T (pt) * | 2010-03-03 | 2016-11-16 | Teva Pharma | Tratamento de artrite causada por lúpus usando laquinimod |
JP5819328B2 (ja) * | 2010-03-03 | 2015-11-24 | テバ ファーマシューティカル インダストリーズ リミティド | ラキニモドとメトトレキセートとの組合せによる関節リウマチの治療 |
AU2011274502A1 (en) * | 2010-07-09 | 2013-02-28 | Teva Pharmaceutical Industries Ltd. | 5-chloro-4-hydroxy-1-methyl-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide, salts and uses thereof |
SG10201505236YA (en) | 2010-07-09 | 2015-08-28 | Teva Pharma | Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof |
AU2011314411B2 (en) * | 2010-10-14 | 2014-06-12 | Immunahr Ab | 1,2-dihydro-4-hydroxy-2-oxo-quinoline-3-carboxanilides as AhR activators. |
FR2967353B1 (fr) * | 2010-11-16 | 2013-08-16 | Centre Nat Rech Scient | Derives de quinolinone |
FR2967498B1 (fr) * | 2010-11-16 | 2015-01-02 | Centre Nat Rech Scient | Utilisation de derives de quinolinone comme outil de recherche |
US8889627B2 (en) | 2011-10-12 | 2014-11-18 | Teva Pharmaceutical Industries, Ltd. | Treatment of multiple sclerosis with combination of laquinimod and fingolimod |
US9206128B2 (en) | 2011-11-18 | 2015-12-08 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
EP2780013A4 (en) | 2011-11-18 | 2015-07-01 | Constellation Pharmaceuticals Inc | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF |
CN104093310A (zh) | 2012-02-03 | 2014-10-08 | 泰华制药工业有限公司 | 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途 |
CA2862289C (en) | 2012-02-10 | 2019-11-26 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
EP2744498A4 (en) | 2012-02-16 | 2014-12-03 | Teva Pharma | N-ETHYL-N-PHENYL-1,2-DIHYDRO-4,5-DI-HYDROXY-1-METHYL-2-OXO-3-CHINOLINE CARBOXAMIDE AND THE PREPARATION AND USE THEREOF |
TW201350467A (zh) | 2012-05-08 | 2013-12-16 | Teva Pharma | N-乙基-4-羥基-1-甲基-5-(甲基(2,3,4,5,6-五羥基己基)胺基)-2-側氧-n-苯基-1,2-二氫喹啉-3-甲醯胺 |
TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
BR112015010193A2 (pt) | 2012-11-07 | 2017-07-11 | Teva Pharma | sais de amina de laquinimod |
KR20150143499A (ko) | 2013-03-14 | 2015-12-23 | 테바 파마슈티컬 인더스트리즈 리미티드 | 라퀴니모드 나트륨의 결정 및 이의 개선된 제조방법 |
WO2014151142A1 (en) | 2013-03-15 | 2014-09-25 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
US9969716B2 (en) | 2013-08-15 | 2018-05-15 | Constellation Pharmaceuticals, Inc. | Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof |
MX2016013944A (es) | 2014-04-29 | 2017-01-09 | Teva Pharma | Laquinimod para el tratamiento de pacientes con esclerosis multiple recidivante-remitente (rrms) con un alto estado de discapacidad. |
WO2017040190A1 (en) | 2015-08-28 | 2017-03-09 | Constellation Pharmaceuticals, Inc. | Crystalline forms of (r)-n-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1h-indole-3-carboxamide |
US10457640B2 (en) | 2016-10-19 | 2019-10-29 | Constellation Pharmaceuticals, Inc. | Synthesis of inhibitors of EZH2 |
GB202006390D0 (en) | 2020-04-30 | 2020-06-17 | Aqilion Ab | Novel treatments |
WO2021237112A1 (en) * | 2020-05-21 | 2021-11-25 | Stemsynergy Therapeutics, Inc. | Notch inhibitors and uses thereof |
CN111732540B (zh) * | 2020-07-20 | 2020-11-13 | 湖南速博生物技术有限公司 | 一种罗喹美克的制备方法 |
WO2023039275A1 (en) | 2021-09-13 | 2023-03-16 | Eli Lilly And Company | Ahr agonists |
WO2024097606A1 (en) | 2022-10-31 | 2024-05-10 | Eli Lilly And Company | Ahr agonists |
WO2024107555A1 (en) | 2022-11-15 | 2024-05-23 | Eli Lilly And Company | Ahr agonists |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH471784A (de) * | 1966-01-26 | 1969-04-30 | Bayer Ag | Verfahren zur Herstellung von Carbostyrilderivaten |
US3524858A (en) * | 1967-05-18 | 1970-08-18 | Warner Lambert Pharmaceutical | 1,4 - dihydro-1-substituted alkyl-6,7-methylenedioxy - 4 - oxoquinoline-3-carboxylic acid |
CH578535A5 (en) | 1973-05-11 | 1976-08-13 | Ciba Geigy Ag | Quinoline-3-carboxylic acid derivs - with e.g. analgesic, antinociceptive, antiinflammatory and antiallergic props |
CA1034124A (en) * | 1973-05-11 | 1978-07-04 | Ciba-Geigy Ag | Process for the manufacture of new quinolines |
CH578537A5 (en) | 1973-05-11 | 1976-08-13 | Ciba Geigy Ag | Quinoline-3-carboxylic acid derivs - with e.g. analgesic, antinociceptive, antiinflammatory and antiallergic props |
CH578536A5 (en) | 1973-05-11 | 1976-08-13 | Ciba Geigy Ag | Quinoline-3-carboxylic acid derivs - with e.g. analgesic, antinociceptive, antiinflammatory and antiallergic props |
CH578534A5 (en) | 1973-05-11 | 1976-08-13 | Ciba Geigy Ag | Quinoline-3-carboxylic acid derivs - with e.g. analgesic, antinociceptive, antiinflammatory and antiallergic props |
US3917609A (en) * | 1973-06-27 | 1975-11-04 | Minnesota Mining & Mfg | Pyrroloquinoline carboxylic acids and derivatives |
FR2281761A1 (fr) * | 1974-08-13 | 1976-03-12 | Roussel Uclaf | Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament |
FR2340735A1 (fr) * | 1976-02-11 | 1977-09-09 | Roussel Uclaf | Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament |
FR2482596A1 (fr) * | 1980-05-19 | 1981-11-20 | Roussel Uclaf | Nouveaux derives de l'acide 4-hydroxy 3-quinoleine carboxylique substitues en 2, leur procede de preparation et leur application comme medicament |
IE52670B1 (en) * | 1981-03-03 | 1988-01-20 | Leo Ab | Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation |
-
1982
- 1982-02-12 IE IE314/82A patent/IE52670B1/en not_active IP Right Cessation
- 1982-02-16 IL IL65028A patent/IL65028A/xx unknown
- 1982-02-22 EP EP82850032A patent/EP0059698B1/en not_active Expired
- 1982-02-22 DE DE8282850032T patent/DE3266464D1/de not_active Expired
- 1982-02-22 US US06/350,890 patent/US4547511A/en not_active Expired - Lifetime
- 1982-02-22 AT AT82850032T patent/ATE15798T1/de not_active IP Right Cessation
- 1982-02-24 ZA ZA821210A patent/ZA821210B/xx unknown
- 1982-02-24 DK DK081282A patent/DK157859C/da not_active IP Right Cessation
- 1982-03-01 FI FI820728A patent/FI79532C/fi not_active IP Right Cessation
- 1982-03-01 NO NO820642A patent/NO163130C/no unknown
- 1982-03-02 NZ NZ199888A patent/NZ199888A/en unknown
- 1982-03-02 HU HU82638A patent/HU186909B/hu unknown
- 1982-03-02 GR GR67454A patent/GR76073B/el unknown
- 1982-03-02 PH PH26933A patent/PH18520A/en unknown
- 1982-03-02 PT PT74512A patent/PT74512B/pt not_active IP Right Cessation
- 1982-03-02 ES ES510042A patent/ES8400409A1/es not_active Expired
- 1982-03-02 CA CA000397413A patent/CA1182455A/en not_active Expired
- 1982-03-03 KR KR8200910A patent/KR860001876B1/ko active
- 1982-03-03 AU AU81076/82A patent/AU547849B2/en not_active Expired
- 1982-03-03 JP JP57033722A patent/JPS57171975A/ja active Granted
-
1985
- 1985-04-16 US US06/723,746 patent/US4738971A/en not_active Expired - Lifetime
-
1989
- 1989-05-11 HK HK386/89A patent/HK38689A/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
US4547511A (en) | 1985-10-15 |
IE52670B1 (en) | 1988-01-20 |
IL65028A0 (en) | 1982-04-30 |
PT74512B (en) | 1983-11-08 |
NZ199888A (en) | 1985-07-31 |
NO820642L (no) | 1982-09-06 |
HK38689A (en) | 1989-05-19 |
IL65028A (en) | 1986-11-30 |
PT74512A (en) | 1982-04-01 |
ZA821210B (en) | 1983-01-26 |
DE3266464D1 (en) | 1985-10-31 |
JPS57171975A (en) | 1982-10-22 |
US4738971A (en) | 1988-04-19 |
NO163130B (no) | 1990-01-02 |
AU547849B2 (en) | 1985-11-07 |
CA1182455A (en) | 1985-02-12 |
FI820728L (fi) | 1982-09-04 |
JPH049786B2 (ko) | 1992-02-21 |
EP0059698B1 (en) | 1985-09-25 |
AU8107682A (en) | 1982-09-09 |
EP0059698A1 (en) | 1982-09-08 |
KR860001876B1 (ko) | 1986-10-24 |
FI79532B (fi) | 1989-09-29 |
PH18520A (en) | 1985-08-02 |
DK81282A (da) | 1982-09-04 |
ES510042A0 (es) | 1983-10-16 |
NO163130C (no) | 1990-04-11 |
ES8400409A1 (es) | 1983-10-16 |
FI79532C (fi) | 1990-01-10 |
DK157859B (da) | 1990-02-26 |
DK157859C (da) | 1990-07-30 |
ATE15798T1 (de) | 1985-10-15 |
IE820314L (en) | 1982-09-03 |
GR76073B (ko) | 1984-08-03 |
HU186909B (en) | 1985-10-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR830009037A (ko) | 헤테로고리 카르복사미드의 제조방법 | |
HUT41770A (en) | Process for producing indol derivatives containing heterocyclic substituents and pharmaceutical compositions containing them | |
HUT59394A (en) | Process for producing piperazine derivatives and pharmaceutical compositions comprising same | |
ES250753A1 (es) | Procedimiento para la obtencion de los anhidridos y amidas de acido graso 0, 0-dialquilditiofosforilico utilizables como materias activas para los insecticidas | |
PT87277A (pt) | Process for the preparation of new bicyclic compounds and pharmaceutical compositions comprising same | |
ATE53034T1 (de) | Verfahren zur herstellung von cephemverbindungen. | |
SE8405275D0 (sv) | 1,2-dithiolan derivatives, processes for their production, pharmaceutical compositions containing them and their use | |
ES8200681A1 (es) | Procedimiento para la preparacion de derivados de 5,11-dihi-dro-6h-pirido(2,3-b)(1,4)-benzodiazepin-6-ona | |
DE2335990C3 (de) | Verfahren zur Formylierung organischer basischer Stickstoffverbindungen | |
US3895022A (en) | Anti-inflammatory agents, cosmetic preparations and method of preventing inflammation | |
KR890002174A (ko) | 삼환성 세팜 화합물, 그의 제조방법 및 용도 | |
US3813360A (en) | 7h-thiazolo(3,2-a)pyrimidin-7-ones | |
US3202666A (en) | Substituted 9h-pyrido (3-4-b) indole-1 carboxylic acid and derivatives | |
ES449817A1 (es) | Procedimiento para producir 2-fenilamino-tiazolinas susti- tuidas. | |
GB1047061A (en) | Polymers and a process for the preparation thereof | |
RU2008129613A (ru) | Способ получения производных эпотилона, новые производные эпотилона, а также новые промежуточные соединения для реализации способа и способы их получения | |
BR8206537A (pt) | Processo para a preparacao de anidridos de acido carboxilico | |
JPH0256476A (ja) | フラン誘導体の製造法 | |
US3816414A (en) | Omikron-acylamino-n-(2-thiazolin-2-yl and 2-thiazin-2-yl)anilines and derivatives thereof | |
JPS54112891A (en) | Preparation of 7-substituted aminocephalosporanic acid derivative | |
GB1156854A (en) | Lactones of Optically Active Heterocyclic Amino Acids and Process for the Preparation thereof | |
DE3937171A1 (de) | Picolylselenobenzamide von aminopyridinen, anilinen und picolylaminen | |
JPS6256475A (ja) | 5−ハロピリジン−3−カルボキサミド化合物 | |
JPS5527111A (en) | Preparation of cephapirin | |
GB1047135A (en) | Cyclopentane carboxylic acid derivatives |